NSE: GUFICBIO · BSE: 509079
GUFIC BIOSCIENCES LTD.
Manufactures and markets pharmaceutical formulations across critical care, women's health, and aesthetics, alongside bulk drugs (APIs). In the segment data for the year-to-date period ending September 2018, the Pharma (formulations) stream was 92.4% of segment revenue at ₹159.06 cr with EBIT of ₹29.11 cr, while Bulk Drugs was 7.1% at ₹12.15 cr. Operating scale includes a lyophilised injectables plant at Indore that reached 30% capacity utilisation and EBITDA breakeven in Q4 FY26, with 40 tech transfers completed, 27 in the pipeline, 200+ state FDA approvals, and an EU GMP certificate pending from a December 2025 audit. The international business is shifting from distributor-held to in-house marketing authorisations via an Ireland-based subsidiary, with new approvals in Myanmar, Philippines, South Africa, Colombia, Germany and Ecuador, and a global-health partnership covering 109 countries. On the domestic side, the women's health franchise holds category leadership in Ferticare and recorded its strongest year in gonadotropins; the aesthetics franchise sits at #2 in Indian botulinum toxin with ~23% share (~3.5-4% of revenue), and a Canadian filler/biostimulator in-licensing deal targets a Q3-Q4 FY27 launch. Q4 FY26 revenue was ₹252 cr (the strongest quarter on record); full-year FY26 revenue was ₹940.5 cr (+14.7% YoY) with EBITDA margin at 16.26%. Materials are the largest cost at 45.1% of revenue, followed by employee cost (16.1%), other opex (23.3%) and depreciation (3.3%). Gross debt sits around ₹400 cr against ~₹75 cr cash, with ₹20 cr per year of replacement capex and no greenfield spend planned for the next two years. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharma (formulations) (92%), Bulk Drugs (7%), Unallocable Income (1%). Pharmaceutical formulations plus APIs plus contract manufacturing; asset-heavy with lyophilised injectables and APIs plants at Indore and Navsari.
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 807 | 820 | 944 |
| EBITDA (ex other income) | 146 | 135 | 151 |
| margin % | 18.1 | 16.4 | 16.0 |
| Owners' profit | 86 | 0 | 0 |
| EPS, as reported (₹) | 8.74 | 6.95 | 6.40 |
| ROE % · ROCE % | 16.2 · 18.2 | 11.6 · 15.0 | 9.7 · 14.9 |
| Debt / equity (x) | 0.60 | 0.52 | 0.58 |
| Cash from operations | (7) | 123 | 45 |
| Capex | (113) | (76) | (31) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 |
| Profit before tax | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 |
| Net profit | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 |
| EPS (₹) | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 57.5 | 30.8 | 124 of 158 | 22% |
| P/B | 6.3 | 3.1 | 135 of 163 | 17% |
| ROCE | 10.5 | 10.8 | 94 of 183 | 49% |
| ROE | 9.7 | 9.8 | 84 of 166 | 50% |
| Debt / Equity | 0.6 | 0.2 | 142 of 166 | 15% |
| EBITDA margin | 18.0 | 17.5 | 79 of 165 | 52% |
| Revenue growth | 16.6 | 16.3 | 79 of 161 | 51% |
| Profit growth | 70.7 | 30.9 | 48 of 158 | 70% |
| Market cap | 4224 | 806 | 62 of 181 | 66% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · USFDA issues three observations after Indore plant pre-approval inspection | regulatory legal | high | — | — |
| 17 Oct 2026 · Notice on special window for re-lodging physical share transfers and demat | compliance | minimal | — | — |
| 6 Oct 2026 · RTA compliance certificate for Q2 FY27 filed with exchanges | compliance | minimal | — | — |
| 29 Sept 2026 · Gufic Biosciences wins appeal against Rs 4.33 cr income tax demand | regulatory legal | high | — | — |
| 28 Sept 2026 · Trading Window closed ahead of Q2 FY27 results | compliance | minimal | — | — |
| 28 Sept 2026 · Gufic Biosciences gets CRISIL ESG rating of 62, Category Strong | business updates | medium | — | — |
| 24 Sept 2026 · NSE rejects waiver; Gufic to pay Rs 1.72 lakh penalty by Oct 3 | regulatory legal | high | — | — |
| 8 Sept 2026 · CRISIL Reaffirms Ratings; Bank Facilities Enhanced to Rs 516 Crore | credit debt | medium | — | — |
| 7 Sept 2026 · Gufic Biosciences 42nd AGM: 5 resolutions passed, Re 0.10 dividend declared | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 42nd AGM proceedings: 5 resolutions passed, Re.0.10 final dividend declared | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.